New Daily Herald

Leading News Provider

Intravitreal Ivt Injectable Market Chronic Retinal Conditions to Uplift Sales of Anti-VEGF IVT Injectables

Rising Prevalence of Retinal Diseases Will Support the Growth of Intravitreal (IVT) Injectables Market

Vitreo-retinal disease has been a major cause of blindness and visual impairment worldwide. Millions of people suffer from retinal disorders, which often lead to loss of vision or complete blindness. Some of the common retinal degenerative diseases are age-related macular degeneration, diabetic macular edema, diabetic retinopathy and others. According to the latest statistics gathered during the study, more than 70 million people are suffering from age-related macular degeneration. Intravitreal (IVT) injectables constitute a key component of the retinal disease treatment. Patients having chronic retinal diseases often require repeated dosages of intravitreal (IVT) injectables and thus, the intravitreal (IVT) injectables market is likely to grow at a significant pace during the forecast period.

Anti-VEGF Therapy Is Likely to Propel Sales of Intravitreal (IVT) Injectables

Since the introduction of anti-VEGF drugs in 2006, intravitreal (IVT) injectables have gained immense popularity among retinal specialists. Anti-VEGF drugs mostly target chronic retinal diseases, such as diabetic retinopathy, macular degeneration, retinal vein occlusion and others. Rising prevalence of these chronic diseases has led to the growth of the anti-VEGF drugs market, which in turn, will lead to high demand for intravitreal (IVT) injectables. Anti-VEGF drugs have proven to be safe for intraocular use as they reduce leakage of fluid in case of eye disorders. Intravitreal (IVT) injectables of anti-VEGF has become the most common and widely used procedure among ophthalmologists and thus, demand for Intravitreal (IVT) Injectables will increase in near future.

Growing Demand for Intravitreal (IVT) Injectables to be Seen in Administration of Medication for Intraocular Diseases

Intravitreal (IVT) Injectables are gaining popularity among retinal specialists as they are more efficient and safe when compared to systemic treatment options for intraocular diseases. However, based on patient journey, intravitreal (IVT) injectables can create complications at a later stage. Intravitreal (IVT) injectables are used in a wide variety of settings to deliver effective treatment for numerous retinal diseases. They can be used to deliver treatment related to anticancer agents, antivascular endothelial growth factor, anti-inflammatory agents, antimicrobials, surgical gases and other pharmaceutical agents. Since intravitreal (IVT) injectables deliver a wide range of medications effectively to treat retinal disorders, they have become commonly used procedures for intraocular use and thus, the Intravitreal (IVT) Injectables market is anticipated to witness high growth in near future.

New Pipeline Drugs for Intraocular Treatment to Hold Significant Impact on Intravitreal (IVT) Injectables Market Performance

Many manufacturers are focusing on developing novel drugs to treat intraocular diseases and meet the unmet needs of patients. Numerous manufacturers are developing products for different indications, which will likely be administered using intravitreal (IVT) injectables. However, ophthalmologists are seeking new advancements in technology to reduce the burden of intravitreal (IVT) injectables used for intraocular diseases. Upcoming new innovative drugs and latest technologies will stimulate the growth of the Intravitreal (IVT) Injectables market. For example, ESBA 1008, developed by Alcon Pharmaceuticals, is currently in Phase II for macular degeneration. This drug will use the intravitreal route of administration. Similarly, CNTO 2476 developed by Janseen Pharmaceuticals is also in Phase II for age-related macular degeneration and will be administered through the intravitreal route of administration.

Competitive Landscape of Global Intravitreal Injectables (IVT) Market

The competition section of the Intravitreal (IVT) Injectables market provides detailed information about key players competing in the Intravitreal Injectables (IVT) market based on their market shares, market strategies, product offerings, marketing approach and company dashboard. Some of the key players featured in this Intravitreal (IVT) Injectables market report include F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Novartis AG, Allergan, Alimera Sciences, ThromboGenics, Inc. and Bristol-Myers Squibb Company.

Definition

An Intravitreal (IVT) Injectables is an effective mode of treatment used in the management of retinal diseases, such as diabetic retinopathy, macular degeneration, retinal vein occlusion and others. Intravitreal Injectables include drug classes, such as anti-VEGF and corticosteriods, which are widely used medications in the treatment of retinal degenerative diseases.

About the Report

The company has conducted a research study on the Intravitreal (IVT) Injectables market for the forecast period 2018 to 2028. The study provides a thorough assessment of opportunities in the Intravitreal (IVT) Injectables market. It also provides an understanding of the populations at risk, pipeline assessment analysis and epidemiology analysis and competition in the Intravitreal (IVT) Injectables market. Further, the report provides thorough information regarding the macroeconomic factors affecting the dynamics in the Intravitreal (IVT) Injectables market

Segmentation

The report comes with the taxonomy of the Intravitreal (IVT) Injectables market. The Intravitreal (IVT) Injectables market has been segmented on the basis of drug class, indication, distributional channel and region. Intravitreal (IVT) Injectables segmented on the basis of drug class into anti-VEGF, corticosteroids, antibiotics, antivirals and antifungals. The Intravitreal (IVT) Injectables market has been segmented on the basis of indication into diabetic retinopathy, macular degeneration, endophthalmitis, retinal vein occlusions and others. By distributional channel, the Intravitreal (IVT) Injectables market has been segmented into hospital pharmacies, retail pharmacies, drug stores, mail order pharmacies and others.

Additional Questions Answered

Some of the additional questions answered in this report on Intravitreal (IVT) Injectables market are:

  • What is the revenue potential of the Intravitreal (IVT) Injectables market across North America and Europe?
  • Who are the key players and what are their product portfolios in the Intravitreal (IVT) Injectables market?
  • What are the major challenges impacting the growth of the Intravitreal (IVT) Injectables market?
  • What are the reimbursement guidelines for Intravitreal (IVT) Injectables prescriptions?

Request For Report Sample@ https://www.persistencemarketresearch.com/samples/25906

Research Methodology

The Intravitreal (IVT) Injectables market has been studied from a supply-demand side approach. Further, qualitative factors impacting the Intravitreal (IVT) Injectables market, such as awareness regarding Intravitreal (IVT) Injectables and treatments available, cost of treatment, reimbursement scenario and others, have also been discussed in this market report. The calculated data has been further validated through primary research, including telephonic interviews, surveys, in-person interactions and viewpoints of experienced analysts. Secondary research resources, such as databases, trade journals and verified paid sources, were used to arrive at the observations drawn. The research study on the Intravitreal (IVT) Injectables also discusses prominent trends and macro as well as microeconomic factors influencing the Intravitreal (IVT) Injectables market.

Leave a Reply

Your email address will not be published. Required fields are marked *